Immunotherapies, biosimilars to dominate next week of earnings

AbbVie, Bristol-Myers, Roche and others will report first quarter earnings over the coming days. 

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • April 24, 2018

Fresenius dumps $4.3B Akorn merger

The German drugmaker contends an internal probe found FDA data breaches, but Akorn denies any wrongdoing.

By Lisa LaMotta • April 23, 2018

Biogen, facing questions, turns again to Ionis in $1B research deal

Tapping the discovery expertise of Ionis, however, may not placate investors eager to see Biogen pad its pipeline with more aggressive dealmaking. 

By Ned Pagliarulo • April 20, 2018

Prescribed Reading: Shire on the block; FDA flip-flops

There are potentially multiple suitors looking to take out Shire. Elsewhere, the FDA is making surprise reversals.

By Lisa LaMotta • April 20, 2018

ApolloBio picks up I/O therapies for China market

Rising cancer rates in China have drawn the attention of drugmakers, spurring increased R&D for therapies designed for Chinese patients. 

By Suzanne Elvidge • April 20, 2018

Shire rejects $62B offer from Takeda, while Allergan weighs bid

The Irish pharma has spurned three offers from the Japanese drugmaker; and now, Allergan confirms it is considering an offer as well. 

By Lisa LaMotta • Updated April 19, 2018

P&G absorbs German Merck's consumer business for $4B

Merck KGaA's consumer health business rose 6% between 2015 and 2017, making it an attractive asset for P&G, which has struggled to deliver growth.

By Jacob Bell • April 19, 2018

Pushing 'value,' Harvard Pilgrim tests outcomes deals

An agreement with AstraZeneca for the pharma's lung drug Symbicort is the ninth value-based contract publicly announced by the regional insurer.

By Ned Pagliarulo • April 18, 2018

ArQule sells off cancer drug rights to Basilea

After a late-stage clinical setback last year, ArQule will trade rights to its lead candidate for some upfront cash.

By Lisa LaMotta • April 18, 2018

Sanofi nears deal to sell EU generics unit for $2.4B

The French drugmaker's decision to divest the business is yet another sign of the pressures facing the generic drug industry.

By Ned Pagliarulo • April 17, 2018

Is 'BerkshAmazMorgan' testing a cure for what ails US healthcare?

This merger just might be a new healthcare model in the making, one that leverages consumer data to deliver real change on the employee health and wellness front while remaking the way that healthcare is paid for.

By Paul Darling and Pratap Khedkar • April 17, 2018

Kineta, Roche's Genentech strike chronic pain deal

Kineta's first big pharma deal could speed development of a potential disease-modifying pain drug.

By Suzanne Elvidge • April 16, 2018

Shire's oncology exit weighs on potential Takeda bid

Analysts expect a $2.4 billion deal with Servier to give Shire more negotiating power with Takeda, but it likely won't keep the suitor at bay.

By Jacob Bell • April 16, 2018

Prescribed Reading: Novartis ups the ante in gene therapy, while GSK folds on the space

Big pharmas are placing their bets on the future of gene therapy, with one European company going all-in and another pulling out.

By Lisa LaMotta • April 13, 2018

Alexion broadens pipeline with $855M Wilson Therapeutics buy

The deal hands Alexion WTX101, a candidate in Phase 3 testing for a rare genetic condition called Wilson's disease.

By Jacob Bell • April 11, 2018

Novartis buys AveXis for $8.7B, broadening gene therapy bet

Acquiring the U.S. biotech and its late-stage candidate for spinal muscular atrophy is new CEO Vas Narasimhan's first major deal as Novartis chief.

By Ned Pagliarulo • April 9, 2018

Ferring picks up microbiome specialist Rebiotix

The Swiss pharma brings in a microbial approach to C diff. infections by buying a microbiome pipeline.

By Suzanne Elvidge • April 6, 2018

Autolus pairs up with Miltenyi to manufacture T-cell therapies

Autolus aims to automate its cell processing steps utilizing Miltenyi tools, which could in theory make the complex manufacturing process more reproducible.

By Randi Hernandez • April 5, 2018

Boehringer joins checkpoint inhibitor race with OSE deal

In a heavily back-ended agreement, Boehringer is betting on a second wave of I/O drug development through the exploration of targets other than PD-1/L1.

By Ned Pagliarulo • April 5, 2018

Novo charts course for sickle cell amid headwinds in hemophilia

The Danish drugmaker lined up $400 million for access to a young biotech's investigational therapy.

By Jacob Bell • April 5, 2018

Lilly's next diabetes play would have patients implanted with engineered stem cells

In addition to an equity investment and $63 million upfront, Lilly's latest deal dangles $410 million in milestones to Sigilon Therapeutics.

By Jacob Bell • April 4, 2018

Pfizer inks deal handing CAR-T assets to newly launched biotech

The new biotech, which will be 25% owned by Pfizer, will be headed by former Kite execs looking to find success in developing allogeneic CAR-T therapy.

By Randi Hernandez • April 3, 2018

Walmart reportedly in early talks to acquire Humana

The companies already partner on Medicare Part D drug plans. But a deal could boost Humana's group market offerings to compete with other insurers, suggests one analyst.

By David Lim • April 2, 2018

Eisai partners with Nichi-Iko in generics pact

Under the deal, Eisai will transfer ownership of its generics unit to Nichi-Iko, supplying its new partner with API from a manufacturing plant in India.

By Ned Pagliarulo • March 29, 2018

Celgene, bluebird revise deal to co-develop CAR-T therapy

The market doesn't seem impressed by the updated agreement between the companies.

By Suzanne Elvidge • March 29, 2018